T-3262 IN UROLOGY
-
- MIYAKITA HIDESHI
- Department of Urology, School of Medicine, Tokai University
-
- TANAKA MOTOAKI
- Department of Urology, School of Medicine, Tokai University
-
- HIHARA TOHRU
- Department of Urology, School of Medicine, Tokai University
-
- NAKAJIMA NOBORU
- Department of Urology, School of Medicine, Tokai University
-
- HOSHINO HIDEAKI
- Department of Urology, School of Medicine, Tokai University
-
- NAGATA YOSHIHIRO
- Department of Urology, School of Medicine, Tokai University
-
- KATSUOKA YOJI
- Department of Urology, School of Medicine, Tokai University
-
- KINOSHITA HIDECHIKA
- Department of Urology, School of Medicine, Tokai University
-
- KAWAMURA NOBUO
- Department of Urology, School of Medicine, Tokai University
-
- MATSUSHITA KAZUO
- Department of Urology, Tokai University Tokyo Hospital
-
- TANIKAWA KATSUMI
- Department of Urology, Tokai University Tokyo Hospital
-
- OHKOSHI MASAAKI
- Department of Urology, Tokai University Tokyo Hospital
-
- OKADA KEISHI
- Department of Urology, Tokai University Oiso Hospital
-
- NISHIZAWA KAZUAKI
- Department of Urology, Tokai University Oiso Hospital
Bibliographic Information
- Other Title
-
- 泌尿器科領域におけるT-3262の臨床的検討
Description
We clinically investigated T-3262, a new antimicrobial agent derived from pyridone-carboxylic acid.<BR>Twenty-five patients with urinary tract infection were treated with T-3262, and the clinical efficacy in 24 patients was evaluated by the criteria of the Japanese UTI Committee. The clinical response in 15 cases of acute uncomplicated cystitis was excellent in 10 cases and moderate in 5 and in both cases of acute uncomplicated pyelonephritis it was excellent. The overall clinical efficacy rate for acute uncomplicated UTI was 100%. The clinical response in 7 patients with chronic complicated cystitis was excellent in 4, the overall efficacy rate being 57.1%. The efficacy was fair in 1 case of chronic complicated pyelonephritis according to the evaluation of the doctor in charge.<BR>Bacteriological response was evaluated in the above 24 cases. Eradication of bacteria was observed in all 17 strains isolated (100%) in uncomplicated UTI and in 6 of 10 strains (60%) in complicated UTI. No adverse reactions were seen.<BR>Our results suggest that T-3262 is useful in treating urinary tract infections.
Journal
-
- CHEMOTHERAPY
-
CHEMOTHERAPY 36 (Supplement9-Clinical), 935-942, 1988
Japanese Society of Chemotherapy
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282681262413056
-
- NII Article ID
- 130004196672
-
- ISSN
- 18845894
- 00093165
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed